{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T05:01:26Z","timestamp":1748926886210,"version":"3.30.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eNeurologicalSci"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ensci.2024.100534","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T07:44:34Z","timestamp":1731483874000},"page":"100534","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["De novo myasthenia gravis in a patient with malignant melanoma after concurrent SARS-CoV-2 vaccination and immune checkpoint inhibitor therapy: Case report and literature review"],"prefix":"10.1016","volume":"37","author":[{"given":"Mohadese","family":"Shahin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedram","family":"Fadavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Mostafa Ansari","family":"Ramandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Shahrokh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Taghizadeh-Hesary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ensci.2024.100534_bb0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ensci.2024.100534_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ensci.2024.100534_bb0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with Cancer treated with immune checkpoint inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ensci.2024.100534_bb0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejca.2021.07.017","article-title":"COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"155","author":"Chen","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ensci.2024.100534_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100272","article-title":"A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1\/PD-L1 inhibitors: a longitudinal cohort study","volume":"6","author":"Lasagna","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ensci.2024.100534_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-021-01046-w","article-title":"COVID-19 vaccines for patients with Cancer: benefits likely outweigh risks","volume":"14","author":"Hwang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ensci.2024.100534_bb0035","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41591-021-01387-6","article-title":"Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2","volume":"27","author":"Au","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ensci.2024.100534_bb0040","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.6004\/jnccn.2022.7048","article-title":"Immune-related adverse events among COVID-19\u2013vaccinated patients with cancer receiving immune checkpoint blockade","volume":"20","author":"Widman","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ensci.2024.100534_bb0045","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2024.42.16_suppl.2648","article-title":"The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors","volume":"42","author":"Guo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ensci.2024.100534_bb0050","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00262-021-03133-w","article-title":"Immune-related adverse events of COVID-19 vaccination in skin Cancer patients receiving immune-checkpoint inhibitor treatment","volume":"71","author":"Strobel","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ensci.2024.100534_bb0055","doi-asserted-by":"crossref","first-page":"2207438","DOI":"10.1080\/21645515.2023.2207438","article-title":"Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors","volume":"19","author":"Gilbert","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ensci.2024.100534_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ensci.2024.100534_bb0065","first-page":"231","article-title":"Cardiac markers in the early diagnosis and Management of Patients with acute coronary syndrome","volume":"9","author":"Al-Hadi","year":"2009","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"10.1016\/j.ensci.2024.100534_bb0070","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s10067-016-3242-9","article-title":"Causes of creatine kinase levels greater than 1000 IU\/L in patients referred to rheumatology","volume":"35","author":"Leverenz","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ensci.2024.100534_bb0075","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12029-020-00454-4","article-title":"Recommendations on management of locally advanced rectal cancer during the COVID-19 pandemic: an Iranian consensus","volume":"51","author":"Siavashpour","year":"2020","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.ensci.2024.100534_bb0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3947\/ic.2020.52.4.496","article-title":"Decision on chemotherapy amidst COVID-19 pandemic: a review and a practical approach from Iran","volume":"52","author":"Rakhsha","year":"2020","journal-title":"Infect. Chemother."},{"key":"10.1016\/j.ensci.2024.100534_bb0085","article-title":"Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study","author":"Naranbhai","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ensci.2024.100534_bb0090","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s11357-021-00471-6","article-title":"Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans","volume":"43","author":"V\u00e1lyi-Nagy","year":"2021","journal-title":"Geroscience"},{"key":"10.1016\/j.ensci.2024.100534_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mito.2023.04.001","article-title":"COVID-19 induced liver injury from a new perspective: mitochondria","volume":"70","author":"Akbari","year":"2023","journal-title":"Mitochondrion"},{"key":"10.1016\/j.ensci.2024.100534_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.617089","article-title":"Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases","volume":"11","author":"Vojdani","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ensci.2024.100534_bb0105","doi-asserted-by":"crossref","first-page":"10881","DOI":"10.3390\/ijms231810881","article-title":"Understanding the pharmacology of COVID-19 mRNA vaccines: playing dice with the spike?","volume":"23","author":"Cosentino","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ensci.2024.100534_bb0110","doi-asserted-by":"crossref","first-page":"1008420","DOI":"10.3389\/fmicb.2022.1008420","article-title":"The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 Nucleocapsid, besides spike protein in healthy adults","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ensci.2024.100534_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.annonc.2022.10.002","article-title":"Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy","volume":"34","author":"Hua","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ensci.2024.100534_bb0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-018-0353-7","article-title":"Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events","volume":"6","author":"L\u00e4ubli","year":"2018","journal-title":"J. Immunother. Cancer"}],"container-title":["eNeurologicalSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650224000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405650224000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T09:41:09Z","timestamp":1733046069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405650224000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"alternative-id":["S2405650224000418"],"URL":"https:\/\/doi.org\/10.1016\/j.ensci.2024.100534","relation":{},"ISSN":["2405-6502"],"issn-type":[{"type":"print","value":"2405-6502"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De novo myasthenia gravis in a patient with malignant melanoma after concurrent SARS-CoV-2 vaccination and immune checkpoint inhibitor therapy: Case report and literature review","name":"articletitle","label":"Article Title"},{"value":"eNeurologicalSci","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ensci.2024.100534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100534"}}